MEA Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
Middle East and Africa natural killer (NK) cell therapeutics market is projected to register a CAGR of 37.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation
Middle East and Africa Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Middle East and Africa natural killer (NK) cell therapeutics market are:
• Increase In Patient Population With Chronic Diseases
• Increasing Investment In Research And Development
• Adoption of natural killer (NK) cell therapy in emerging markets
Market Players
The key market players for Middle East and Africa natural killer (NK) cell therapeutics market are listed below:
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Company Profiles
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Therapeutics Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Secondary Sources
- 2.11 Assumptions
- 3 Executive Summary
- 3.1 Epidemiology
- 3.2 Pestel Analysis
- 3.3 Porter’s Five Forces Model
- 3.4 Industrial Insights:
- 3.5 Pipeline Analysis
- 4 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Regulations
- 5 Market Overview
- 5.1 Drivers
- 5.1.1 Increase In Usage Of Natural Killer (Nk) Cells For The Treatment Of Cancer And Infectious Diseases
- 5.1.2 Increase In Patient Population With Chronic Diseases
- 5.1.3 Rise In Awareness About Immunotherapies
- 5.1.4 Adoption Of Natural Killer (Nk) Cell Therapy In Emerging Markets
- 5.2 Restraints
- 5.2.1 Lack Of Specificity And Poor In-vivo Survival Of The Cells
- 5.2.2 Adverse Side Effects Of Therapies
- 5.2.3 High Cost Associated With The Therapies
- 5.3 Opportunities
- 5.3.1 Advancement In Natural Killer (Nk) Cell Therapies
- 5.3.2 Strategic Initiatives By Market Players
- 5.3.3 Rise In Expenditure In Healthcare Sector
- 5.4 Challenges
- 5.4.1 Long Approval Time For Immunotherapies
- 5.4.2 Lack Of Specific Treatment By Natural Killer (Nk) Cells
- 5.4.3 Availability Of Alternatives For Tumor Treatment
- 6 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics
- 6.1 Overview
- 6.2 Nk Cell Therapies
- 6.3 Nk Cell Directed Antibodies
- 7 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Approaches
- 7.1 Overview
- 7.2 Antibody-dependent Cell-mediated Cytotoxicity (Adcc)
- 7.3 Bispecific Antibodies
- 8 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Application
- 8.1 Overview
- 8.2 Cancer
- 8.2.1 Solid Tumors
- 8.2.2 Hematologic Malignancies
- 8.2.2.1 Multiple Myeloma
- 8.2.2.2 Acute Myeloid Leukemia (Aml)
- 8.2.2.3 Lymphoma
- 8.2.2.4 Others
- 8.2.3 Others
- 8.3 Immunoproliferative Disorders
- 8.4 Acute Infectious Diseases
- 8.5 Gastrointestinal Diseases
- 8.6 Others
- 9 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By End User
- 9.1 Overview
- 9.2 Hospitals
- 9.3 Specialty Clinics
- 9.4 Research & Academic Institutes
- 10 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel
- 10.1 Overview
- 10.2 Hospital Pharmacies
- 10.3 Direct Tender
- 10.4 Others
- 11 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Region
- 11.1 Middle East & Africa
- 11.1.1 Saudi Arabia
- 11.1.2 South Africa
- 11.1.3 U.A.E
- 11.1.4 Israel
- 11.1.5 Kuwait
- 11.1.6 Egypt
- 11.1.7 Rest Of Middle East & Africa
- 12 Middle East & Africa Natural Killer (Nk) Cells Therapeutics Market, Company Landscape
- 12.1 Company Share Analysis: Middle East & Africa
- 13 Swot Analysis
- 14 Company Profile
- 14.1 Merck Kgaa
- 14.1.1 Company Snapshot
- 14.1.2 Recent Financials
- 14.1.3 Product Portfolio
- 14.1.4 Recent Developments
- 14.2 Bristol-myers Squibb Company
- 14.2.1 Company Snapshot
- 14.2.2 Recent Financials
- 14.2.3 Product Portfolio
- 14.2.4 Recent Developments
- 14.3 Glycostem
- 14.3.1 Company Snapshot
- 14.3.2 Product Portfolio
- 14.3.3 Recent Developments
- 14.4 Innate Pharma, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Revenue Analysis
- 14.4.3 Product Portfolio
- 14.4.4 Recent Developments
- 14.5 Regeneron Pharmaceuticals Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Recent Financials
- 14.5.3 Product Portfolio
- 14.5.4 Recent Developments
- 14.6 Takeda Pharmaceutical Company Limited
- 14.6.1 Company Snapshot
- 14.6.2 Recent Financials
- 14.6.3 Product Portfolio
- 14.6.4 Recent Developments
- 14.7 Inmunebio
- 14.7.1 Company Snapshot
- 14.7.2 Revenue Analysis
- 14.7.3 Product Portfolio
- 14.7.4 Recent Developments
- 14.8 Kiadis Pharma
- 14.8.1 Company Snapshot
- 14.8.2 Revenue Analysis
- 14.8.3 Product Portfolio
- 14.8.4 Recent Developments
- 14.9 Acepodia Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Product Portfolio
- 14.9.3 Recent Developments
- 14.10 Affimed Gmbh
- 14.10.1 Company Snapshot
- 14.10.2 Recent Financials
- 14.10.3 Product Portfolio
- 14.10.4 Recent Developments
- 14.11 Biohaven Pharmaceuticals
- 14.11.1 Company Snapshot
- 14.11.2 Revenue Analysis
- 14.11.3 Product Portfolio
- 14.11.4 Recent Developments
- 14.12 Brink Biologics, Inc.
- 14.12.1 Company Snapshot
- 14.12.2 Product Portfolio
- 14.12.3 Recent Development
- 14.13 Cytovia Therapeutics
- 14.13.1 Company Snapshot
- 14.13.2 Product Portfolio
- 14.13.3 Recent Developments
- 14.14 Emercell
- 14.14.1 Company Snapshot
- 14.14.2 Product Portfolio
- 14.14.3 Recent Developments
- 14.15 Fate Therapeutics
- 14.15.1 Company Snapshot
- 14.15.2 Revenue Analysis
- 14.15.3 Product Portfolio
- 14.15.4 Recent Developments
- 14.16 Gamida Cell
- 14.16.1 Company Snapshot
- 14.16.2 Product Portfolio
- 14.16.3 Recent Developments
- 14.17 Icell Gene Therapeutics
- 14.17.1 Company Snapshot
- 14.17.2 Product Portfolio
- 14.17.3 Recent Development
- 14.18 Immunitybio, Inc.
- 14.18.1 Company Snapshot
- 14.18.2 Revenue Analysis
- 14.18.3 Product Portfolio
- 14.18.4 Recent Developments
- 14.19 Multimmune Gmbh
- 14.19.1 Company Snapshot
- 14.19.2 Product Portfolio
- 14.19.3 Recent Developments
- 14.20 Nektar
- 14.20.1 Company Snapshot
- 14.20.2 Revenue Analysis
- 14.20.3 Product Portfolio
- 14.20.4 Recent Developments
- 14.21 Nkarta, Inc.
- 14.21.1 Company Snapshot
- 14.21.2 Product Portfolio
- 14.21.3 Recent Developments
- 14.22 Persongen Biotherapeutics
- 14.22.1 Company Snapshot
- 14.22.2 Product Portfolio
- 14.22.3 Recent Developments
- 14.23 Phio Pharmaceuticals
- 14.23.1 Company Snapshot
- 14.23.2 Product Portfolio
- 14.23.3 Recent Developments
- 15 Questionnaire
- 16 Related Reports
- List Of Tables
- Table 1 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, Pipeline Analysis
- Table 2 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 3 Middle East & Africa Nk Cell Therpaies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 4 Middle East & Africa Nk Cell Directed Antibodies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 5 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 6 Middle East & Africa Antibody-dependent Cell-mediated Cytotoxicity (Adcc) In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 7 Middle East & Africa Bi-specific Antibodies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 8 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Application, 2019-2027 (Usd Million)
- Table 9 Middle East & Africa Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 10 Middle East & Africa Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 11 Middle East & Africa Hematologic Malignancies In Cancer Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 12 Middle East & Africa Others In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 13 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 14 Middle East & Africa Hospitals In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 15 Middle East & Africa Specialty Clinics In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 16 Middle East & Africa Research And Academic Institutes In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 17 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2027 (Usd Million)
- Table 18 Middle East & Africa Hospital Pharmacies In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2027 (Usd Million)
- Table 19 Middle East & Africa Direct Tender In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2027 (Usd Million)
- Table 20 Middle East & Africa Others In Natural Killer (Nk) Cell Therapeutics Market, By Region, 2018-2029 (Usd Million)
- Table 21 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Country, 2018-2029 (Usd Million)
- Table 22 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 23 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 24 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 25 Middle East & Africa Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 26 Middle East & Africa Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 27 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 28 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 29 Saudi Arabia Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 30 Saudi Arabia Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 31 Saudi Arabia Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 32 Saudi Arabia Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 33 Saudi Arabia Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 34 Saudi Arabia Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 35 Saudi Arabia Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 36 South Africa Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 37 South Africa Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 38 South Africa Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 39 South Africa Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 40 South Africa Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 41 South Africa Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 42 South Africa Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 43 U.A.E Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 44 U.A.E Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 45 U.A.E Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 46 U.A.E Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 47 U.A.E Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 48 U.A.E Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 49 U.A.E Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 50 Israel Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 51 Israel Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 52 Israel Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 53 Israel Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 54 Israel Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 55 Israel Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 56 Israel Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 57 Kuwait Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 58 Kuwait Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 59 Kuwait Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 60 Kuwait Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 61 Kuwait Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 62 Kuwait Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 63 Kuwait Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 64 Egypt Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- Table 65 Egypt Natural Killer (Nk) Cell Therapeutics Market, By Approaches, 2018-2029 (Usd Million)
- Table 66 Egypt Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 67 Egypt Cancer In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 68 Egypt Hematologic Malignancies In Natural Killer (Nk) Cell Therapeutics Market, By Application, 2018-2029 (Usd Million)
- Table 69 Egypt Natural Killer (Nk) Cell Therapeutics Market, By End User, 2018-2029 (Usd Million)
- Table 70 Egypt Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel, 2018-2029 (Usd Million)
- Table 71 Rest Of Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics, 2018-2029 (Usd Million)
- List Of Figures
- Figure 1 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Segmentation
- Figure 2 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market : Data Triangulation
- Figure 3 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Droc Analysis
- Figure 4 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Middle East & Africa Vs Regional Market Analysis
- Figure 5 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Company Research Analysis
- Figure 6 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Multivariate Modelling
- Figure 7 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Interview Demographics
- Figure 8 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Dbmr Market Position Grid
- Figure 9 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Vendor Share Analysis
- Figure 10 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Segmentation
- Figure 11 North America Is Expected To Dominate And Asia-pacific Is Growing With The Fastest Pace In The Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market In The Forecast Period Of 2022 To 2029
- Figure 12 Increase In Usage Of Natural Killer Cells For The Treatment Of Cancer And Infectious Diseases And Rise In The Awareness About Immunotherapies Is Driving The Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market In The Forecast Period Of 2022 To 2029
- Figure 13 Nk Cell Therapies Segment Is Expected To Account For The Largest Share Of The Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market In 2022 & 2029
- Figure 14 Drivers, Restraints, Opportunities, And Challenges Of Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market
- Figure 15 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, 2021
- Figure 16 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, 2022-2029 (Usd Million)
- Figure 17 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, Cagr (2022-2029)
- Figure 18 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, Lifeline Curve
- Figure 19 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Approaches, 2021
- Figure 20 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Approaches, 2022-2029 (Usd Million)
- Figure 21 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Approaches, Cagr (2022-2029)
- Figure 22 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Approaches, Lifeline Curve
- Figure 23 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Application, 2020
- Figure 24 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Application, 2022-2029 (Usd Million)
- Figure 25 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Application, Cagr (2022-2029)
- Figure 26 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Application, Lifeline Curve
- Figure 27 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By End User, 2021
- Figure 28 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By End User, 2022-2029 (Usd Million)
- Figure 29 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By End User, Cagr (2022-2029)
- Figure 30 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By End User, Lifeline Curve
- Figure 31 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, 2021
- Figure 32 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, 2022-2029 (Usd Million)
- Figure 33 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, Cagr (2022-2029)
- Figure 34 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, Lifeline Curve
- Figure 35 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 36 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 37 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 38 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 39 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 40 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Company Share 2021 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook